Afya
Track in portfolio
Price chart
Description
Company and Business Model
Afya operates in the consumer defensive sector, primarily focusing on educational services for healthcare professionals in Brazil. Its core offerings include online courses, medical education, and certification programs. The company generates revenue through course enrollments and partnerships with educational institutions. Afya's business segments encompass digital education platforms and traditional educational services, catering to a growing demand for healthcare training in the region.
Investment Profile
The stock presents a balanced investment profile, appealing to investors seeking moderate growth potential without significant risk exposure. It may attract those interested in stable earnings rather than high dividends or aggressive growth. The company's consistent performance and educational focus suggest a reliable, if not high-yield, investment opportunity.
Fundamental metrics (experimental) Updated: 2026-11-21
- EPS (TTM) — earnings per share for the last 12 months, $
- 8.96
- Revenue QoQ — quarter-over-quarter revenue growth
- 0.7%
- EPS surprise
- 8.1%
- 20d volatility
- 2.1%
- Dividend yield
- 6.4%
- last ex-date
- 2026-03-25
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-10-27 | Buy | Sell | High risk with significant negative momentum and weak fundamentals. |
| 2026-10-15 | Hold | Buy | Stable dividend, moderate growth, but cautious market signals. |
| 2026-10-08 | — | Hold | Mixed performance; cautious outlook amid market uncertainty. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-11-05 | Morgan Stanley | Update | — → 12.6 | 10.5 |
| 2026-11-03 | Citigroup | Update | — → 16 | 10.55 |
| 2026-10-29 | Bank of America Securities | Update | — → 16 | 10.17 |
| 2026-09-24 | Bradesco | Rating Upgraded | — → 17 | 13.5313 |
| 2026-02-13 | Morgan Stanley | Rating Downgraded | — → 16 | 14.49 |
| 2026-01-21 | BTG Pactual | Rating Downgraded | — → 17 | 13.66 |
| 2026-01-16 | UBS | Update | — → 16 | 14.39 |
| 2026-01-08 | UBS | Target Lowered | 19 → 18 | 14.9 |